Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
-
1621
-
1622
-
1623
Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
-
1624
Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
-
1625
Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
-
1626
Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx
Published 2025“…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
-
1627
Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff
Published 2025“…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
-
1628
-
1629
-
1630
-
1631
-
1632
-
1633
-
1634
-
1635
-
1636
-
1637
-
1638
Table1_Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway.DOCX
Published 2025“…However, there are no drugs available in the clinic to relieve it at present. Astragaloside IV (AS-IV) is a saponin extract of the Astragalus which is widely used in the treatment of kidney disease. …”
-
1639
Table1_Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway.DOCX
Published 2025“…However, there are no drugs available in the clinic to relieve it at present. Astragaloside IV (AS-IV) is a saponin extract of the Astragalus which is widely used in the treatment of kidney disease. …”
-
1640
Image1_Comprehensive analysis of Hibisci mutabilis Folium extract’s mechanisms in alleviating UV-induced skin photoaging through enhanced network pharmacology and experimental vali...
Published 2024“…In vitro experiments showed that EHMF significantly reduced UV-induced inflammatory factors in HaCaT cells and improved cell survival rates. …”